Michael C Heinrich
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009; 8:2621-30.
Aug 24, 2009The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Aug 24, 2009Cell Cycle 2009; 8:2621-30
Schittenhelm Marcus, Kampa-Schittenhelm Kerstin, Yee Kevin W H, Heinrich Michael C
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Schittenhelm M, Bokemeyer C, Wong K, Corless C, Kanz L, Störkel S, Kurek R, Honecker F, Morich J, Harlow A, Oechsle K, Kollmannsberger C, Heinrich M. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009; 8:481-9.
Mar 10, 2009Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Mar 10, 2009Mol Cancer Ther 2009; 8:481-9
Schittenhelm Marcus, Bokemeyer Carsten, Wong Kwok-Kin, Corless Christopher L, Kanz Lothar, Störkel Stephan, Kurek Raffael, Honecker Friedemann, Morich Jason, Harlow Amy, Oechsle Karin, Kollmannsberger Christian, Heinrich Michael C
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12:501-13.
Dec 1, 2007Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Dec 1, 2007Cancer Cell 2007; 12:501-13
Fröhling Stefan, Jiang Jingrui, Schittenhelm Marcus, Lee Benjamin H, Griffin James D, Stone Richard M, Heinrich Michael C, Deininger Michael W, Druker Brian J, Golub Todd R, Teckie Sewit, Ebert Benjamin L, Scholl Claudia, Levine Ross L, Loriaux Marc, Boggon Titus J, Bernard Olivier A, Berger Roland, Döhner Hartmut, Döhner Konstanze, Gilliland D Gary
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Schittenhelm M, Druker B, Deininger M, Bokemeyer C, Lee F, Griffith D, Corbin A, Schroeder A, Shiraga S, Heinrich M. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-81.
Jan 1, 2006Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Jan 1, 2006Cancer Res 2006; 66:473-81
Schittenhelm Marcus, Druker Brian J, Deininger Michael W N, Bokemeyer Carsten, Lee Francis Y, Griffith Diana, Corbin Amie S, Schroeder Arin, Shiraga Sharon, Heinrich Michael C
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
Yee K, Schittenhelm M, O'Farrell A, Town A, McGreevey L, Bainbridge T, Cherrington J, Heinrich M. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104:4202-9.
Aug 10, 2004Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
Aug 10, 2004Blood 2004; 104:4202-9
Yee Kevin W H, Schittenhelm Marcus, O'Farrell Anne-Marie, Town Ajia R, McGreevey Laura, Bainbridge Troy, Cherrington Julie M, Heinrich Michael C